Pembrolizumab was given as an intravenous infusion of 200 mg every 3 weeks, for a total of 17 doses (approximately 1 year)
The FDA said the conditions created the risk that the products could be contaminated with filth or rendered injurious to health. Sure enough, the regulator documented three ER visits after patients taking a product containing NAD+ compounded by GenoGenix
A lower dose of 200 mg/day did not significantly affect blood lead concentration, although serum vitamin C concentrations were not different from those in the group who took 1,000 mg/day
Supports those seeking to enhance their skin's natural glow from within through simple, easy-to-take powder format
10.2353/ajpath.2009.080804 113
Most of the studies included were rated as very low quality, and the authors stress the need for more high-quality RCTs to improve confidence in the results